ATE544455T1 - Zusammensetzungen und verfahren für die krebsbehandlung - Google Patents

Zusammensetzungen und verfahren für die krebsbehandlung

Info

Publication number
ATE544455T1
ATE544455T1 AT07862970T AT07862970T ATE544455T1 AT E544455 T1 ATE544455 T1 AT E544455T1 AT 07862970 T AT07862970 T AT 07862970T AT 07862970 T AT07862970 T AT 07862970T AT E544455 T1 ATE544455 T1 AT E544455T1
Authority
AT
Austria
Prior art keywords
compositions
methods
cancer treatment
cancer
treatment
Prior art date
Application number
AT07862970T
Other languages
English (en)
Inventor
Hanno Roder
Original Assignee
Tautatis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tautatis Inc filed Critical Tautatis Inc
Application granted granted Critical
Publication of ATE544455T1 publication Critical patent/ATE544455T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT07862970T 2006-12-14 2007-12-14 Zusammensetzungen und verfahren für die krebsbehandlung ATE544455T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87501306P 2006-12-14 2006-12-14
PCT/US2007/025692 WO2008076394A1 (en) 2006-12-14 2007-12-14 Compositions and methods for the treatment of cancer

Publications (1)

Publication Number Publication Date
ATE544455T1 true ATE544455T1 (de) 2012-02-15

Family

ID=39536630

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07862970T ATE544455T1 (de) 2006-12-14 2007-12-14 Zusammensetzungen und verfahren für die krebsbehandlung

Country Status (7)

Country Link
US (2) US8022056B2 (de)
EP (1) EP2124554B1 (de)
JP (1) JP2010513287A (de)
AT (1) ATE544455T1 (de)
AU (1) AU2007334381B2 (de)
CA (1) CA2672650C (de)
WO (1) WO2008076394A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004025726B4 (de) * 2004-05-26 2006-07-06 Roder, Hanno, Dr. Verwendung eines spezifischen K252a-Derivats zur Verhinderung oder Behandlung der Alzheimerschen Krankheit
JP2010513287A (ja) * 2006-12-14 2010-04-30 トータティス， インク． 癌治療のための組成物及び方法
US20100273769A1 (en) * 2009-01-26 2010-10-28 Hanno Roder Composition and method for the treatment of parkinson's disease
WO2013059320A1 (en) * 2011-10-17 2013-04-25 Board Of Regents, The University Of Texas System Treatment of cancers with mutant npm1 with mek inhibitors
CN107936043B (zh) * 2017-12-11 2019-01-01 南京诺赛德生物技术有限公司 一种具有抗肿瘤活性物质及其合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG18188A (en) * 1986-05-01 1992-09-30 Pfizer Ltd Process for preparation anti-arhythmia agents
WO1997005140A1 (en) 1995-07-31 1997-02-13 Novartis Ag Trindene compounds
JP2000516250A (ja) * 1996-08-22 2000-12-05 ブリストルーマイヤーズ スクイブ カンパニー インドロピロロカルバゾールの細胞毒性アミノ糖および関連する糖誘導体
JP4405667B2 (ja) * 1997-12-31 2010-01-27 セフアロン・インコーポレーテツド Ｋ−２５２ａの３’−エピマー誘導体
US6013646A (en) * 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US7129250B2 (en) * 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
US6677450B2 (en) * 2000-10-06 2004-01-13 Bristol-Myers Squibb Company Topoisomerase inhibitors
US20050171182A1 (en) * 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
DE102004025726B4 (de) * 2004-05-26 2006-07-06 Roder, Hanno, Dr. Verwendung eines spezifischen K252a-Derivats zur Verhinderung oder Behandlung der Alzheimerschen Krankheit
JP2010513287A (ja) * 2006-12-14 2010-04-30 トータティス， インク． 癌治療のための組成物及び方法

Also Published As

Publication number Publication date
EP2124554A1 (de) 2009-12-02
US20120202789A1 (en) 2012-08-09
CA2672650C (en) 2015-09-08
EP2124554A4 (de) 2009-12-30
CA2672650A1 (en) 2008-06-26
JP2010513287A (ja) 2010-04-30
US8022056B2 (en) 2011-09-20
AU2007334381B2 (en) 2014-02-13
EP2124554B1 (de) 2012-02-08
WO2008076394A1 (en) 2008-06-26
AU2007334381A1 (en) 2008-06-26
US20080255087A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
FR21C1063I1 (fr) Traitement combiné de tumeurs exprimant la cd38
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
BRPI0915084B8 (pt) composto, e, composição farmacêutica
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
NO20092637L (no) Fremgangsmater for behandling
TW200716606A (en) Chemical compounds
TW200800963A (en) Chemical compounds
EA201170832A1 (ru) Пуриновые соединения
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
EA201170521A1 (ru) Новые соединения
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
CY1112889T1 (el) Αναλογα αζετιδινης αναστολεων νουκλεοσιδασης και φωσφορυλασης
UA107783C2 (en) Isoindoline compounds for use in treating cancer
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
WO2007097981A3 (en) Alpha carbolines and uses thereof
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MY147634A (en) New crystalline forms
ATE544455T1 (de) Zusammensetzungen und verfahren für die krebsbehandlung